Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Conclusion: For children, adolescents, and young adults with standard-risk R/R cHL prior to ASCT, this risk-stratified, response-adapted approach using nivo, BV, and bendamustine resulted in high CMR rates and was well tolerated, making it a promising novel salvage therapy. Most evaluated patients achieved CMR with IND (nivo + BV); all 6 who went to INT (BV + bendamustine) achieved CMR. Updated results based on a planned interim analysis including more patients and BICR-assessed response data will be presented.Study support: Sponsored by Bristol-Myers Squibb in collaboration with Children's Oncology Group (COG) and EuroNet group.DisclosuresLeger: Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Brugieres: Takeda: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Other: Financial support for SIOP meeting in 2016. Galderisi: Seattle Genetics: Employment, Equity Ownership. Sacchi: Bristol-Myers Squibb: Employment, Equity Ownership. Jou: Bristol-Myers Squibb: Employment, Other: company stock ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Harker-Murray, P., Leblanc, T., Mascarin, M., Mauz-Korholz, C., Michel, G., Cooper, S., Beishuizen, A., Leger, K. J., Garaventa, A., Buffardi, S., Brugieres, L., Kelly, K. M., Cole, P. D., Drachtman, R. A., Galderisi, F., Sacchi, M., Jou, Y.-M., Daw, S. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches Source Type: research